The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women: A Randomized Controlled Trial
Open accessAbstract
Abstract Postmenopausal hormone replacement therapy is associated with a reduction in the incidence of coronary heart disease. However, inconclusive results have been reported with respect to the risk of stroke, and recent studies consistently showed an increased risk of venous thromboembolism in postmenopausal women using oral estrogen. There are surprisingly few interventional studies to assess the true effects of estrogen-progestin regimens on blood coagulation and fibrinolysis, and the impact of the route of estrogen administration on hemostasis has not been well documented. Therefore, we investigated the effects of oral and transdermal estradiol/progesterone replacement therapy on hemostatic variables. Forty-five healthy postmenopausal women, aged 45 to 64 years, were assigned randomly to one of the three following groups: cyclic oral or transdermal estradiol, both combined with progesterone, or no hormonal treatment. Hemostatic variables were assayed at baseline and after a 6-month period. Pairwise differences in the mean change between the three groups were compared using nonparametric tests. Oral but not transdermal estradiol regimen significantly increased the mean value of prothrombin activation peptide (F1+2) and decreased mean antithrombin activity compared with no treatment. Differences in fragment F1+2 levels between active treatments were significant. The oral estrogen group was associated with a significant decrease in both mean tissue-type plasminogen (t-PA) concentration and plasminogen activator inhibitor (PAI-1) activity and a significant rise in global fibrinolytic capacity (GFC) compared with the two other groups. A transdermal estrogen regimen had no significant effect on PAI-1, t-PA, and GFC levels. There were no significant changes in mean values of fibrinogen, factor VII, von Willebrand factor, protein C, fibrin D-dimer, and plasminogen between and within the three groups. We conclude that oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis. Whereas these results may account for an increased risk of venous thromboembolism in users of oral postmenopausal estrogen, they emphasize the potential importance of the route of estrogen administration in prescribing hormone replacement therapy to postmenopausal women, especially to those at high risk of thrombotic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens
Clauss, A. (1957) · Acta Haematologica · doi:10.1159/000205234 · Cited by 3,208
Valery (1995) · doi:10.1001/jama.1995.03520270033028 · Cited by 2,320
Meade, T. W., Brozovic, M., Chakrabarti, R. R., Haines, A. P., Imeson, J. D., Mellows, S., Miller, G. J., North, W. R. S., Stirling, Y., & Thompson, S. G. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90111-x · Cited by 1,939
Thompson, S. G., Kienast, J., Pyke, S. D. M., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,821
Lerner, D. J., & Kannel, W. B. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90155-9 · Cited by 1,725
Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Grodstein, F., Stampfer, M. J., Manson, J. E., Colditz, G. A., Willett, W. C., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350701 · Cited by 1,305
Nabulsi, A. A., Folsom, A. R., White, A., Patsch, W., Heiss, G., Wu, K. K., & Szklo, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304153281501 · Cited by 906
Fibrinogen and Risk of Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1987) · JAMA · doi:10.1001/jama.1987.03400090067035 · Cited by 886
Risk of venous thromboembolism in users of hormone replacement therapy
Daly, E., Vessey, M. P., Hawkins, M. M., Carson, J. L., Gough, P., & Marsh, S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07113-9 · Cited by 819
Jick, H., Jick, S. S., Myers, M. W., Vasilakis, C., & Gurewich, V (1995) · The Lancet · doi:10.1016/s0140-6736(95)91928-7 · Cited by 726
Adams, M. R., Kaplan, J. R., Manuck, S. B., Koritnik, D. R., Parks, J. S., Wolfe, M. S., & Clarkson, T. B. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.6.1051 · Cited by 605
Jick, H., Derby, L. E., Myers, M. W., Vasilakis, C., & Newton, K. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07114-0 · Cited by 602
Prospective study of exogenous hormones and risk of pulmonary embolism in women
Grodstein, F., Stampfer, M. J., Goldhaber, S. Z., Manson, J. E., Colditz, G. A., Speizer, F. E., Willett, W. C., & Hennekens, C. H. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07308-4 · Cited by 571
Juhan-Vague, I., Pyke, S. D. M., Alessi, M. C., Jespersen, J., Haverkate, F., & Thompson, S. G. (1996) · Circulation · doi:10.1161/01.cir.94.9.2057 · Cited by 552
Morrissey, J., Macik, B., Neuenschwander, P., & Comp, P. (1993) · Blood · doi:10.1182/blood.v81.3.734.734 · Cited by 512
Bauer, K., & Rosenberg, R. (1987) · Blood · doi:10.1182/blood.v70.2.343.343 · Cited by 389
Hormonal Treatment of Postmenopausal Women
Wood, A. J. J., & Belchetz, P. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404143301508 · Cited by 384
Balleisen, L., Bailey, J., Epping, P.-H., Schulte, H., & van de Loo, J. (1985) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657877 · Cited by 346
Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors
FOLSOM, A., WU, K., DAVIS, C., CONLAN, M., SORLIE, P., & SZKLO, M. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90167-2 · Cited by 321
Prospective study of endogenous tissue plasminogen activator and risk of stroke
Ridker, P. M., Hennekens, C. H., Manson, J. E., Ridker, P. M., Vaughan, D. E., Stampfer, M. J., Vaughan, D. E., Hennekens, C. H., & Stampfer, M. J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90064-7 · Cited by 305
Gebara, O. C. E., Mittleman, M. A., Sutherland, P., Lipinska, I., Matheney, T., Xu, P., Welty, F. K., Wilson, P. W. F., Levy, D., Muller, J. E., et al. (1995) · Circulation · doi:10.1161/01.cir.91.7.1952 · Cited by 298
(1996) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(96)89711-6 · Cited by 259
Biological Effects of Estradiol-17β in Postmenopausal Women: Oral Versus percutaneous Administration
LIGNIERS, B. D., BASDEVANT, A., THOMAS, G., THALABARD, J.-C., MERCIER-BODARD, C., CONARD, J., GUYENE, T.-T., MAIRON, N., CORVOL, P., GUY-GRAND, B., et al. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-3-536 · Cited by 230
Coagulation Activation Following Estrogen Administration to Postmenopausal Women
Caine, Y. G., Bauer, K. A., Barzegar, S., ten Cate, H., Sacks, F. M., Walsh, B. W., Schiff, I., & Rosenberg, R. D. (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646283 · Cited by 201
Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women
Guetta, V., & Cannon, R. O. (1996) · Circulation · doi:10.1161/01.cir.93.10.1928 · Cited by 201
Manolio, T. A., Furberg, C. D., Shemanski, L., Psaty, B. M., O'Leary, D. H., Tracy, R. P., & Bush, T. L. (1993) · Circulation · doi:10.1161/01.cir.88.5.2163 · Cited by 194
Plasminogen Activator Inhibitor 1 and Atherothrombosis
Juhan-Vague, I., & Alessi, M. C. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646175 · Cited by 192
Estrogen replacement therapy and the risk of venous thrombosis
Devor, M., Barrett-Connor, E., Renvall, M., Feigal, D., & Ramsdell, J. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90077-o · Cited by 177
Increased Activation of the Haemostatic System in Men at High Risk of Fatal Coronary Heart Disease
Miller, G. J., Bauer, K. A., Barzegar, S., Cooper, J. A., & Rosenberg, R. D. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650364 · Cited by 168
The Effects of Transdermal Estradiol and Oral Conjugated Estrogens on Haemostasis Variables
Kroon, U. ‐., Silfverstolpe, G., & Tengborn, L. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1642453 · Cited by 148
Use of "off-label" and unlicensed drugs in paediatric intensive care unit
Turner, S. C. M., Gill, A. M., Nunn, T., Hewitt, B., & Choonara, I. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91182-4 · Cited by 129
Population Correlates of Coagulation Factor VII
Scarabin, P., Vissac, A., Kirzin, J.-M., Bourgeat, P., Amiral, J., Agher, R., & Guize, L. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.9.1170 · Cited by 92
Self-citationHemostatic factors according to menopausal status and use of hormone replacement therapy
Meilahn, E. N., Kuller, L. H., Matthews, K. A., & Kiss, J. E. (1992) · Annals of Epidemiology · doi:10.1016/1047-2797(92)90094-7 · Cited by 90
MENOPAUSAL STATUS AND HAEMOSTATIC VARIABLES
Meade, T. W. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91562-3 · Cited by 87
Psaty, B. M. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410120009002 · Cited by 86
Lindberg, U.-B., Crona, N., Stigendal, L., Teger‐Nilsson, A. ‐., & Silfverstolpe, G. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646528 · Cited by 80
Meade, T. W. (1996) · BMJ · doi:10.1136/bmj.312.7029.473 · Cited by 75
Conard, J., Basdevant, A., Thomas, J.-L., Ochsenbein, E., Denis, C., Guyene, T. T., & Degrelle, H. (1995) · Fertility and Sterility · doi:10.1016/s0015-0282(16)57909-6 · Cited by 74
The Writing Group for the Estradiol Clotting Factors Study (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650300 · Cited by 70
Lee, A. J., Lowe, G. D. O., Smith, W. C., & Tunstall‐Pedoe, H. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb04699.x · Cited by 68
Relation of Hormone-Replacement Therapy to Measures of Plasma Fibrinolytic Activity
Shahar, E., Folsom, A. R., Salomaa, V. V., Stinson, V., McGovern, P. G., Shimakawa, T., Chambless, L. E., & Wu, K. K. (1996) · Circulation · doi:10.1161/01.cir.93.11.1970 · Cited by 67
Boschetti, C., Cortellaro, M., Nencioni, T., Bertolli, V. G., Volpe, A. D., & Zanussi, C. (1991) · Thrombosis Research · doi:10.1016/0049-3848(91)90663-h · Cited by 53
Salomaa, V. V., Rasi, V., Pekkanen, J., Vahtera, E. M., Jauhiainen, M., Vartiainen, E. A., Ehnholm, C., Tuomilehto, J., & Myllylä, G. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.10.1549 · Cited by 52
Factor VII activation and menopausal status
Scarabin, P., Bonithon‐Kopp, C., Bara, L., Malméjac, A., Guize, L., & Samama, M. M. (1990) · Thrombosis Research · doi:10.1016/0049-3848(90)90322-4 · Cited by 50
Self-citationScarabin, P., Plu‐Bureau, G., Zitoun, D., Bara, L., Guize, L., & Samama, M. M. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649849 · Cited by 36
Self-citationHormone replacement therapy and hemostasis: principles of a complex interaction
Winkler, U. H. (1996) · Maturitas · doi:10.1016/0378-5122(96)01027-4 · Cited by 36
Safety of combined oral contraceptive pills.
Plu‐Bureau, G., Amiral, J., Guize, L., & Scarabin, P. (1996) · PubMed · Cited by 34
Self-citationDifferential AT III-response to oral and parenteral administration of 17 beta-estradiol.
Conard, J., Samama, M. M., Basdevant, A., Guy-grand, B., & Lignieres, B. D. (1983) · PubMed · Cited by 27
Postmenopausal estrogen and heart disease
Barrett-Connor, E. L. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)90068-3 · Cited by 18
Relationship between plasminogen activator inhibitor activity and menopausal status
Scarabin, P., Bonithon‐Kopp, C., Bara, L., Guize, L., & Samama, M. M. (1990) · Fibrinolysis and Proteolysis · doi:10.1016/0268-9499(90)90020-k · Cited by 11
Self-citation
Cited by
Nelson, L. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0808697 · Cited by 1,158
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., Trillot, N., Barrellier, M.-T., Wahl, D., Emmerich, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.642280 · Cited by 864
Self-citationScarabin, P.-Y., Oger, E., & Plu-Bureau, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14066-4 · Cited by 714
Self-citation
Metadata
- Authors
- Scarabin, P.-Y., Alhenc-Gelas, M., Plu-Bureau, G., Taisne, P., Agher, R., & Aiach, M.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1997-11
- Volume
- 17
- Issue
- 11
- Pages
- 3071-3078
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2072157130
- Cited by
- 348
- References
- 51
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.